Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross ...
GRI Bio, Inc. (NASDAQ: GRI) (“GRI Bio” or the “Company”), a biotechnology company advancing an innovative pipeline of immune cell modulators for the treatment of inflammatory, fibrotic and autoimmune ...
Company reported $8.2 million in cash and cash equivalents at December 31, 2025 and raised additional $6.5 million in gross proceeds in January 2026 Balance sheet strengthened to fund operations into ...
The ruling confirms that alloys are classified by the metal predominating by weight. Since copper predominated, the brass ...
One of the most remarkable discoveries of modern neuroscience is that the adult brain is capable of producing new neurons in various mammalian species, including humans. For more than 30 years, ...
Regency Centers Corporation (“Regency Centers,” “Regency” or the “Company”) (Nasdaq: REG) today reported financial and operating results for the period ended December 31, 2025, and provided initial ...
Manchester United pulled off a dramatic 3-2 win over Fulham at Old Trafford in what was an intense showdown.While the visitors did well to claw their way back from a 2-0 deficit, Man United showed ...
Despite the macroeconomic uncertainty and challenging environment in 2025, the Grainger team continued to execute against our strategy, delivering exceptional service and a best-in-class experience ...
W.W. Grainger, Inc. (NYSE:GWW) Q4 2025 Earnings Call Transcript February 3, 2026 W.W. Grainger, Inc. misses on earnings ...
Early Phase 2a data suggest the IPF therapy GRI-0621 alters gene activity tied to inflammation, scarring, and tissue repair.
If you are wondering whether W.W. Grainger's share price still reflects reasonable value after a strong run over the years, ...
Investing.com -- Grainger on Wednesday delivered solid operational performance in its trading update for the four months ending January 2026, with total like-for-like rental growth of 3.1% and high ...